Evidence map›Paper›PMID 22499853›Full record

ArticleAmerican journal of respiratory cell and molecular biology2012

SPLUNC1 deficiency enhances airway eosinophilic inflammation in mice.

Jyoti V Thaikoottathil, Richard J Martin, Peter Y Di, Maisha Minor, Stephanie Case, Bicheng Zhang, Gongyi Zhang, Hua Huang, Hong Wei Chu

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. A SPLUNC1 Peptidomimetic Inhibits Orai1 and Reduces Inflammation in a Murine Allergic Asthma Model.American journal of respiratory cell and molecular biology · 2022
    Article
  6. SPLUNC1 α6 Peptidomimetic: A Novel Therapeutic for Asthma.American journal of respiratory cell and molecular biology · 2022
    Article
  7. BPIFA1 is a secreted biomarker of differentiating human airway epithelium.Frontiers in cellular and infection microbiology · 2022
    Article
  8. Article
  9. SPLUNC1: a novel marker of cystic fibrosis exacerbations.The European respiratory journal · 2021
    Article
  10. [Antimicrobial peptides and proteins in chronic rhinosinusitis].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jyoti V ThaikoottathilPulmonary Division, Department of Medicine, National Jewish Health, Denver, CO 80206, USA.
Richard J Martin
Peter Y Di
Maisha Minor
Stephanie Case
Bicheng Zhang
Gongyi Zhang
Hua Huang
Hong Wei Chu
National Jewish Health · USPulmonary Associates · USUniversity of Pittsburgh · US

Funding

Epithelial PLUNC as a determinant of Airway Mucosal Antimicrobial ActivityR01HL091938 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DI, YUANPU PETER · 2008 to 2012
$2.3M
SPLUNC1 protein in host defense against Mycoplasma pneumoniae infectionR01HL088264 · NHLBI · NATIONAL JEWISH HEALTH · PI CHU, HONG W · 2009 to 2012
$1.8M
Effects of Allergic Inflammation on TLR2 Signaling and Mycoplasma InfectionR01AI070175 · NIAID · NATIONAL JEWISH HEALTH · PI CHU, HONG W · 2008 to 2011
$1.6M
NHLBI NIH HHS R01 HL088264NHLBI NIH HHS R01 HL091938NIAID NIH HHS R01 AI070175
6 · The paper itself

Abstract

Short palate, lung and nasal epithelium clone 1 (SPLUNC1) is enriched in normal airway lining fluid, but is significantly reduced in airway epithelium exposed to a Th2 cytokine milieu. The role of SPLUNC1 in modulating airway allergic inflammation (e.g., eosinophils) remains unknown. We used SPLUNC1 knockout (KO) and littermate wild-type (C57BL/6 background) mice and recombinant SPLUNC1 protein to determine the impact of SPLUNC1 on airway allergic/eosinophilic inflammation, and to investigate the underlying mechanisms. An acute ovalbumin (OVA) sensitization and challenge protocol was used to induce murine airway allergic inflammation (e.g., eosinophils, eotaxin-2, and Th2 cytokines). Our results showed that SPLUNC1 in the bronchoalveolar lavage fluid of OVA-challenged wild-type mice was significantly reduced (P < 0.05), which was negatively correlated with levels of lung eosinophilic inflammation. Moreover, SPLUNC1 KO mice demonstrated significantly higher numbers of eosinophils in the lung after OVA challenges than did wild-type mice. Alveolar macrophages isolated from OVA-challenged SPLUNC1 KO versus wild-type mice had higher concentrations of baseline eotaxin-2 that was amplified by LPS (a known risk factor for exacerbating asthma). Human recombinant SPLUNC1 protein was applied to alveolar macrophages to study the regulation of eotaxin-2 in the context of Th2 cytokine and LPS stimulation. Recombinant SPLUNC1 protein attenuated LPS-induced eotaxin-2 production in Th2 cytokine-pretreated murine macrophages. These findings demonstrate that SPLUNC1 inhibits airway eosinophilic inflammation in allergic mice, in part by reducing eotaxin-2 production in alveolar macrophages.

Indexed as

AnimalsBronchoalveolar Lavage FluidChemokine CCL24EosinophilsGlycoproteinsHEK293 CellsHumansInterleukin-13Interleukin-4LipopolysaccharidesLungMacrophages, AlveolarMiceMice, Inbred C57BLMice, KnockoutOvalbuminBpifa1 protein, mouseChemokine CCL24GlycoproteinsInterleukin-13Interleukin-4LipopolysaccharidesOvalbuminPhosphoproteinsRecombinant Proteins

Identifiers

PMID22499853
PMCPMC3423460
OpenAlexW2107808188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.